In Vitro and in Vivo Applications of Euphorbia Wallichii Shoot Extract

Total Page:16

File Type:pdf, Size:1020Kb

In Vitro and in Vivo Applications of Euphorbia Wallichii Shoot Extract Green Processing and Synthesis 2021; 10: 101–111 Research Article Rehman Ullah, Sumaira Shah*, Zahir Muhammad, Sajjad Ali Shah, Shah Faisal, Umbreen Khattak, Tauheed ul Haq, and Muhammad Taj Akbar In vitro and in vivo applications of Euphorbia wallichii shoot extract-mediated gold nanospheres https://doi.org/10.1515/gps-2021-0013 nanoparticles at 50, 100, and 200 mg/kg bw. Inhibition of received January 06, 2021; accepted January 26, 2021 gastrointestinal muscular contraction was 21.16%, 30.49%, Abstract: The current study was designed to investigate and 40.19% in mice feed with 50, 100, and 200 mg/kg bw, the potential of Euphorbia wallichii shoot extract for respectively. 3+ reducting Au and stabilizing gold nanoparticles. Keywords: Euphorbia wallichii, gold nanospheres, char- UV-visible spectra of gold nanoparticles showed obvious acterization, in vitro, in vivo applications surface plasmon resonance peak at 548 nm. Microscopy (SEM and TEM) showed spherical dimensions, and the energy dispersive X-ray spectra displayed the strongest optical absorption peak for gold (Au) at 2.1 keV. Dynamic 1 Introduction light scattering spectra represent polydispersed mixture ( ) - with particulate diameter of 2.5–103.2 nm. The IR spectra Centuries ago, gold nanoparticles AuNPs have been uti - confirm the potential functional groups of shoot extract lized by artists due to its interaction with light and cap responsible for the reduction of Au3+ to gold nanoparti- ability to produce attractive colors. Besides, biomedical cles which exhibit tremendous antibacterial potential of and electrical engineers are also taking advantages of the - 76.31%, 68.47%, 79.85%, 48.10%, and 65.53% against interesting and eye catching applications of AuNPs in - Escherichia coli, Staphylococcus aureus, Bacillus pumilus, nanomedicine and electronics. In this aspect, the impor Pseudomonas aeruginosa, and Klebsiella pneumoniae, tance of gold nanospheres cannot be neglected as it is [ ] respectively. Gold nanoparticles showed markedly elevated more potent and advanced than other metallic NPs 1 . fungicidal potency compared to the shoot extract alone Phytomedicines are moving from fringe to a major stream - against the tested fungal strains. IC for 2,2-diphenyl-1- and are used by greater number of people who seek reme 50 ff picrylhydrazyl scavenging was 31.52, 18.29, and 15.32 µg/mL dies for health, with no or low side e ects. In the recent at 30, 60, and 90 min of reaction time, respectively. era, a green route has emerged for NP fabrication, and Both shoot extract and nanoparticles revealed 71% mor- people from both developing and developed countries - tality at 100 µg/mL, with LD values of 310.56 µg/mL. have paid considerable attention to the eco friendly and 90 - - - Experimental mice acquired dose-dependent analgesia bio friendly plant based products in curing and pre [ ] of 54.21%, 82.60%, and 86.53% when treated with gold venting various human diseases 2 . Nano biotechnology is a new frontier for medicine with the application of nano-sized material for targeted cell or tissue-specific clinical intervention. Nanotechnology designed and * Corresponding author: Sumaira Shah, Department of Botany, employed techniques for the synthesis of systems that can Bacha Khan University Charsadda, Charsadda, KPK, Pakistan, ( ) fi- e-mail: [email protected] interact at molecular subcellular level with great speci Rehman Ullah, Zahir Muhammad, Tauheed ul Haq: Department of city in order to achieve maximum therapeutic potency with Botany, University of Peshawar, Peshawar, KPK, Pakistan minimal side effects. The toxic chemicals limit the biome- Sajjad Ali Shah, Shah Faisal: Department of Biotechnology, dical applications of chemically synthesized NPs [3].The Bacha Khan University Charsadda, Charsadda, KPK, Pakistan use of gold in nanostructure has become an attractive area Umbreen Khattak: Department of Botany, Islamia College University, University of Peshawar, Peshawar, KPK, Pakistan of research during last several years because of its diverse Muhammad Taj Akbar: Department of Microbiology, Abdul Wali applications in various fields of science and technology [4]. Khan University Mardan, Mardan, KPK, Pakistan A great deal of efforts has been employed for the biological Open Access. © 2021 Rehman Ullah et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 International License. 102 Rehman Ullah et al. application of AuNPs in drug delivery, bio-diagnostics, bio- 30 min at 35 ± 3°C till the color of the reaction mixture technology, and medicine as metallic gold is biologically changes from pale yellowish to ruby red. After the com- nonreactive [5]. AuNPs have excellent antimicrobial activ- pletion of reaction, the AuNPs is centrifuged and washed ities against a wide of range of microorganisms such as with deionized water through centrifugation. The AuNPs bacteria and fungi [6]. These days AuNPs are used widely were dried through freeze-drying technique. The synthe- in chemical catalysis, nonlinear optics, surface-enhanced sized AuNPs were then stored for further use. Raman scattering, nanoelectronics, gene expression, dis- ease diagnosis, targeted drug delivery, and a controlled release of a drug at the desired site [7]. Similarly, nanoscale particles of gold also caught distinct position in biosensing, 2.3 Characterizations enzyme electrodes, catalysis electronics, super conductors, and cancer therapy [8]. The AuNPs prove overwhelming The reduction of Au ions was confirmed by analyzing photocatalytic and therapeutic properties and are more through UV-visible (UV-Vis) spectroscopic analysis of effective against microbes [9]. the synthesized mixture run against ethanol mixture Both Euphorbia wallichii shoot extract (SE) and and distilled water as a blank. The analysis is carrying AuNPs possess some novel physiological and physio- out using UV-Vis spectrophotometer at a resolution of chemical features such as electromagnetic and thermal 1 nm from 300 to 800 nm. For further characterizations, conductance, intense plasmon resonance, biochemical the selected sample is freeze-dried. stability, catalytic potential, antimicrobial activity, anti- Perkin Elmer spectrometer is used for FT-IR analysis HIV, antiangiogenic agents, antiarthritic, and antimalarial in the range of 4,000–0cm−1 at a resolution of 4 cm−1. activities [10]. The current study is designed to biosynthe- Thin pellets of KBr are prepared by pressing with the size AuNPs from E. wallichii SE and eluate its antimicrobial hydraulic pellet press and the sample was put on KBr and other in vivo and in vitro applications. pellet, which is then subjected to FTIR analysis. After FTIR analysis, the AuNP solution was dried at 90°C for XRD analysis using JEOL JDX-3532 X-ray diffractometer (JDX-3532, JEOL, Japan). The average particle size of 2 Materials and methods AuNPs is calculated from the XRD pattern according to the full width at half maximum (FWHM) of the maximum fl 2.1 Plant collection and preparation of intensity re ection peak. The size of NPs is calculated through the Scherrer’s equation (Eq. 1). extract Kλ D =×100 (1) βθ1 cos E. wallichii shoots is collected from various localities of 2 Khyber Pakhtunkhwa, Pakistan. The plant is identified at where D is the average crystal size, K = 0.89 is the the Department of Botany University of Peshawar, Pakistan. Scherrer coefficient, λ = 1.5406 Å is the X-ray wavelength, A specimen of the collected plant is submitted to herbarium 2θ is the Bragg’s angle, β (β = sample, β reference) is with voucher No. Bot. 20210 (UOP). The shoots are separated FWHM in radians. and washed with distilled water and dried for 1 week in Surface morphology of AuNPs is inspected by using shade. The dry shoots are powdered using an electric FE-SEM. A dried sample of AuNPs is coated on a carbon grinder. The shoot powder of 500 g is soaked in 1,500 mL tape and then with gold before subjecting it to Spi- ethanol for 2 weeks. The extract is filtered through Whatman module sputter coater for analysis. filter paper and then evaporated at 40°C through a rotatory The distribution of AuNPs is evident from the TEM evaporator. The solid product is preserved at 4°C in refrig- image. The synthesized AuNPs is used for the analysis of erator for NP synthesis. particle size. Specimens for TEM analysis are prepared by adding 1 or 2 drops of AuNPs solution onto the copper grids and allowing to dry at normal temperature. TEM (Philips Tacna G2 FEI F12, Brown University, Rhode 2.2 Biosynthesis of AuNPs Island, USA) is used to evaluate the surface morphology and size of NPs. The particles are washed and isolated by The synthesis of AuNPs involved the mixing of 1 mL SE centrifugation method by taking 30 mL of suspension in - solution with 1 mM aqueous solution of HAuCl4 in dif distilled water containing AuNPs for 30 min at 12,000 rpm. ferent ratios (1:1 to 1:5) by volume and stirred for The pellets are collected and dried at 50°C in the oven to Gold nanosphares and their in vitro and in vivo applications 103 remove the rest of the water. The collected sample is used For antispasmodic activity, forenight fasted groups for EDX analysis. AuNPs are dried and drop coated on to of mice were fed with normal saline (10 mL/kg bw), atro- the carbon film. EDX analysis is then carried out by using pine sulfate (10 mg/kg bw), 50 mg/kg bw of each SE and SEM equipped with a thermo EDX attachment. AuNPs (po), 100 mg/kg bw of SE and AuNPs (po),and 200 mg/kg bw of each SE and AuNPs (po). After 15 min, the animals were fed with 0.2 mL of activated charcoal, sacrificed (after 30 min), dissected, and the intestine was 2.4 In vitro bioassay cut down from pyloric to cecum. The distance traveled by the charcoal relative to the total intestinal length was mea- For bactericidal examination, Mueller–Hinton agar was sured as percentage of propulsion.
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub
    US 2004O156872A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0156872 A1 Bosch et al. (43) Pub. Date: Aug. 12, 2004 (54) NOVEL NMESULIDE COMPOSITIONS application No. 09/572,961, filed on May 18, 2000, now Pat. No. 6,316,029. (75) Inventors: H. William Bosch, Bryn Mawr, PA (US); Christian F. Wertz, Brookhaven, Publication Classification PA (US) (51) Int. Cl. ............................ A61K 9/14; A61K 9/00 Correspondence Address: FOLEY AND LARDNER (52) U.S. Cl. ............................................ 424/400; 424/489 SUTE 500 3000 KSTREET NW WASHINGTON, DC 20007 (US) (57) ABSTRACT (73) Assignee: Elan Pharma International Ltd. The present invention provides nanoparticulate nimeSulide (21) Appl. No.: 10/697,703 compositions. The compositions preferably comprise nime (22) Filed: Oct. 31, 2003 Sulide and at least one Surface Stabilizer adsorbed on or asSociated with the Surface of the nimeSulide particles. The Related U.S. Application Data nanoparticulate nimeSulide particles preferably have an effective average particle size of less than about 2000 nm. (63) Continuation-in-part of application No. 10/276,400, The invention also provides methods of making and using filed on Jan. 15, 2003, which is a continuation of nanoparticulate nimeSulide compositions. US 2004/O156872 A1 Aug. 12, 2004 NOVEL NMESULIDE COMPOSITIONS tion;' U.S. Pat. Nos. 5,399,363 and 5,494,683, both for “Surface Modified Anticancer Nanoparticles; U.S. Pat. No. RELATED APPLICATIONS 5,401,492 for “Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents,” 0001. This application is a continuation-in-part of U.S. U.S. Pat. No.
    [Show full text]
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,491,574 Seifter Et Al
    United States Patent (19) 11 Patent Number: 4,491,574 Seifter et al. (45) Date of Patent: Jan. 1, 1985 (54 REDUCTION OF HIGH DOSE ASPIRIN alleviating the adverse side-effects of taking non-steroid TOXICTY BY DETARY WITAMIN A analgesics and anti-inflammatory agents such as aspirin, by also ingesting vitamin A (or B-carotene) formula 75 Inventors: Eli Seifter, New Hyde Park; tions. It has been found that vitamin A ingestion has a Giuseppe Rettura, Bronx, both of salutary and therapeutic effect, in that the vitamin A N.Y. decreases toxicity, including ulcerogenesis, due to in (73) Assignee: Albert Einstein College of Medicine gestion of such agents, e.g. aspirin. Aspirin per se is a of Yeshiva University, a division of very effective medication with pronounced analgesic Yeshiva University, Bronx, N.Y. properties, including the temporary relief of minor (21) Appl. No.: 471,498 aches and pains, and is widely used (in small amounts) with no ill effects. However, since aspirin is a mild (22) Filed: Mar. 2, 1983 anti-coagulant, it sometimes causes bleeding of stomach 51) Int. Cl. .................. A61K 31/605; A61K 31/615 ulcers, or aggravates pre-existing conditions of that 52 U.S. Cl. ...................................... 424/10; 424/233; nature. Thus the concomitant administration of vitamin 424/235 A per se to humans taking aspirin is very effective in 58) Field of Search .......................... 424/10, 233,235 decreasing toxicity and inhibiting ulcerogenesis and (56) References Cited bleeding in the stomach. Also effective, but less so, is B-carotene, a vitamin A precursor, which when assimi U.S.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]